- Home
- GOSS vs SOR Comparison
GOSS vs SOR Comparison
Compare GOSS & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- SOR
- Stock Information
- Founded
- GOSS 2015
- SOR 1968
- Country
- GOSS United States
- SOR United States
- Employees
- GOSS N/A
- SOR N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- GOSS Health Care
- SOR Finance
- Exchange
- GOSS Nasdaq
- SOR Nasdaq
- Market Cap
- GOSS 347.8M
- SOR 364.9M
- IPO Year
- GOSS 2019
- SOR N/A
- Fundamental
- Price
- GOSS $2.47
- SOR $44.50
- Analyst Decision
- GOSS Strong Buy
- SOR
- Analyst Count
- GOSS 4
- SOR 0
- Target Price
- GOSS $8.50
- SOR N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- SOR 16.2K
- Earning Date
- GOSS 08-05-2025
- SOR 01-01-0001
- Dividend Yield
- GOSS N/A
- SOR 7.24%
- EPS Growth
- GOSS N/A
- SOR N/A
- EPS
- GOSS N/A
- SOR 6.50
- Revenue
- GOSS $40,237,000.00
- SOR N/A
- Revenue This Year
- GOSS N/A
- SOR N/A
- Revenue Next Year
- GOSS $30.65
- SOR N/A
- P/E Ratio
- GOSS N/A
- SOR $6.41
- Revenue Growth
- GOSS N/A
- SOR N/A
- 52 Week Low
- GOSS $0.66
- SOR $36.41
- 52 Week High
- GOSS $2.65
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- SOR 63.93
- Support Level
- GOSS $2.38
- SOR $43.65
- Resistance Level
- GOSS $2.65
- SOR $44.86
- Average True Range (ATR)
- GOSS 0.15
- SOR 0.63
- MACD
- GOSS 0.03
- SOR 0.05
- Stochastic Oscillator
- GOSS 76.67
- SOR 68.46
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.